# Commission Regulation (EC) No 508/1999 of 4 March 1999 amending Annexes I to IV to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, Division 1.2.3

Extent: E+W+S+N.I.

Quinolones
Pharmacologically active substance(s)
Marker residue
Animal species
MRLs
Target tissues
Other provisions
Danofloxacin
Danofloxacin
Bovine
200 μg/kg
Muscle
Not for use in animals from which milk is produced for human consumption
100 μg/kg
Fat
400 μg/kg
Liver
400 μg/kg
Kidney
Chicken
200 μg/kg
Muscle
Not for use in animals from which eggs are produced for human consumption
100 μg/kg
Skin and fat
400 μg/kg
Liver
400 μg/kg
Kidney
Difloxacin
Difloxacin
Chicken, turkey
300 μg/kg
Muscle
400 μg/kg
Skin and fat
1 900 μg/kg
Liver
600 μg/kg
Kidney
Enrofloxacin
Sum of enrofloxacin and ciprofloxacin
Bovine
100 μg/kg
Muscle
100 μg/kg
Fat
300 μg/kg
Liver
200 μg/kg
Kidney
100 μg/kg
Milk
Rabbits
100 μg/kg
Muscle
100 μg/kg
Fat
200 μg/kg
Liver
300 μg/kg
Kidney
Porcine
100 μg/kg
Muscle
100 μg/kg
Skin and fat
200 μg/kg
Liver
300 μg/kg
Kidney
Poultry
100 μg/kg
Muscle
Not for use in animals from which eggs are produced for human consumption
100 μg/kg
Skin and fat
200 μg/kg
Liver
300 μg/kg
Kidney
Sarafloxacin
Sarafloxacin
Chicken
10 μg/kg
Skin and fat
100 μg/kg
Liver
Salmonidae
30 μg/kg
Muscle and skin in natural proportions

---
Source: https://www.legislation.gov.uk/eur/1999/508/annex/I/division/1/division/1.2/division/1.2.3 (the official version)
Page: https://openlegislation.uk/eu-regulation-1999-508/annex-I/division-1/division-1.2/division-1.2.3
Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives.